Clinical trials: Swelling
Moderate to Severe Rheumatoid Arthritis
Evaluating Etanercept Use in Patients With Moderate to Severe Rheumatoid Arthritis Who Have Lost Response to Adalimumab
To evaluate the efficacy of etanercept in adults with moderate-to-severe rheumatoid arthritis (RA) who did not respond to or lost a satisfactory response to adalimumab when used as their first biologic agent.
- Trial name
- ROCkIES (NCT01927757)
- Testing
- Etanercept, Methotrexate
- Where
- 45 sites in United States, Canada and 1 more
- Volunteers
- 90 people
- Sponsor
- Amgen
Lower Extremity Swelling Acute
Physician Clinical Trial Policy (CTP) Neurological Ischemia Lower Extremity Pain and Swelling
Physician Clinical Trial Policy (CTP) to evaluate the efficacy treatment of lower extremity pathologies derived from neurological ischemia disorders using the combination of Monochromatic Infrared Photo Energy (MIRE) and…
- Trial name
- DTSC (NCT01979367)
- Testing
- Anodyne
- Volunteers
- 1,000 people
- Sponsor
- American Association of Sensory Electrodiagnostic Medicine
Acute Hereditary Angio Edema
Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks
Prospective, multicenter, randomized, double-blind, parallel group, placebo- controlled, efficacy and safety phase 3 study of an intravenous human plasma- derived C1 esterase inhibitor (C1-INH) concentrate in participants with…
- Trial name
- NCT06361537
- Testing
- OCTA-C1-INH
- Where
- 25 sites in United States, Albania and 11 more
- Volunteers
- 124 people
- Sponsor
- Octapharma
Hereditary Angioedema
Efficacy and Safety of GNR-038 vs Berinert® in Patients With Hereditary Angioedema
It is a placebo-controlled randomized trial to evaluate the efficacy and safety of GNR-038 in comparison with Berinert® in patients with hereditary angioedema
- Trial name
- NCT04898309
- Testing
- GNR-038, 50 МЕ/ kg, GNR-038, 100 МЕ/ kg, Berinert®, 20 МЕ/ kg
- Where
- 5 sites in Russia
- Sponsor
- AO GENERIUM
Osteoarthritis
To Study Generic Diclofenac Sodium Topical Gel 1% in the Treatment of Osteoarthritis of the Knee (Degenerative Joint Disease Presented as Joint Pain, Stiffness, Swelling and Restricted Motion).
This is a Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence of Diclofenac Sodium Gel, 1% (Glenmark Pharmaceuticals Ltd) to Voltaren® Gel…
- Trial name
- NCT02596451
- Testing
- Diclofenac Sodium gel, 1%, Voltaren® Gel
- Where
- 44 sites in United States
- Volunteers
- 1,164 people
- Sponsor
- Glenmark Pharmaceuticals Ltd. India
Post-Dental Gingival Pain, Gingival Swelling
Efficacy and Safety of HA35 Gel for Post-Dental Gingival Pain and Swelling
This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of 10% high-concentration 35 kDa hyaluronan (HA35) gel delivered via gel-soaked cotton balls in patients with gingival pain…
- Conditions
- Post-Dental Gingival Pain, Gingival Swelling, Postoperative Oral Pain, Dental Procedure-Related Discomfort
- Trial name
- HA35 (NCT07584655)
- Testing
- 10% High-Concentration 35 kDa Hyaluronan (HA35) Oral Topical Gel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Nakhia Impex LLC
Pain
Investigation of Kritech Efficacy on Subjects Having Functional Discomfort Associated to Joints and Muscles Disorders
Joints and muscles disorders are common symptoms in the population. They are characterized by swelling, pain, functional impairment and morning stiffness.
- Trial name
- Easykrill (NCT02318875)
- Testing
- Kritech administration
- Where
- France
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Vivatech
Rheumatoid Arthritis
A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate
The purpose of this dose range finding study is to assess the effectiveness, safety and tolerability of JNJ-38518168 at doses of 3, 10, and 30 mg/d compared with placebo in patients with active rheumatoid arthritis (RA) despite…
- Trial name
- NCT01679951
- Testing
- JNJ-38518168 (3 mg), JNJ-38518168 (10 mg), JNJ-38518168 (30 mg)
- Where
- 85 sites in United States, Argentina and 14 more
- Volunteers
- 272 people
- Sponsor
- Janssen Research & Development, LLC
Rheumatoid Arthritis
A Multicentre Trial to Determine the Efficacy of AD 452 in RA Subjects.
AD 452 is a new drug which is being developed for use in adult patients with RA. It is believed that AD 452 may modify the underlying disease of RA as well as improving RA symptoms, and in order to establish its efficacy and…
- Trial name
- NCT00141934
- Testing
- AD 452
- Where
- 10 sites in United States
- Volunteers
- 232 people
- Sponsor
- Sosei
Myopia
Daytime Corneal Swelling During Wear of Narafilcon B Lenses
The purpose of this research is to measure daytime open-eye response to wearing of narafilcon B lenses.
- Trial name
- NCT01444287
- Testing
- narafilcon B, Polymacon, Lotrafilcon A
- Where
- Australia
- Volunteers
- 22 people
- Sponsor
- Johnson & Johnson Vision Care, Inc.
Catheter Site Pain, Catheter Site Discomfort
Investigation of New Intermittent Catheter Swelling Media in Healthy Volunteers
Investigation of novel swelling media for CE marked intermittent urinary catheters. The study was a randomized, single blinded, cross-over investigation comparing a novel swelling media with a comparator swelling media in 22…
- Trial name
- NCT04633291
- Testing
- Novel swelling media, Comparator swelling media
- Where
- Denmark
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Coloplast A/S
Active Rheumatoid Arthritis; Rheumatoid Arthritis
A Dose Range Finding Study of JNJ-39758979 in Patients With Active Rheumatoid Arthritis Currently Treated With Methotrexate
The purpose of the study is to assess the efficacy, safety and tolerability of JNJ-39758979 at doses of 10, 30, 100, and 300 mg/day compared with placebo (inactive medical substance) in patients with active rheumatoid arthritis…
- Trial name
- NCT01480388
- Testing
- JNJ-39758979 (10 mg), JNJ-39758979 (30 mg), JNJ-39758979 (100 mg)
- Sponsor
- Janssen Research & Development, LLC
Osteoarthritis of Knee, Edema
Microcurrent Stimulation Reduces Post-Operative Swelling and Healing Time Following Knee Replacement Surgery
The purpose of this study is to determine if patients undergoing a total knee arthroplasty (TKA) experience a clinically significant reduction in healing time when treated post operatively with a specific form of micro and…
- Conditions
- Osteoarthritis of Knee, Edema, Wounds and Injuries
- Trial name
- NCT02623660
- Testing
- ODIN1, Standard Care, Diagnostic Device Testing
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bioelectric Research Corporation
Lymphedema
Quality of Life Changes on Lower Extremity Lymphedema Patients Using an Advanced Pneumatic Compression Device (PCD)
Assessment of quality of life and symptoms changes in primary or secondary, unilateral or bilateral lower extremity lymphedema patients using an advanced pneumatic compression system.
- Trial name
- NCT02661646
- Testing
- Advanced Pneumatic Compression Device
- Where
- 6 sites in United States
- Volunteers
- 249 people
- Sponsor
- Tactile Medical
Brain Swelling, Large Hemispheric Infarction
A Trial of HRS8179 on Brain Swelling After Large Hemispheric Infarction
The primary objective is to explore if HRS8179 could improve midline shift at 72 hours (or at time of decompressive craniectomy or comfort measures only, if earlier) in participants with large hemispheric infarction.
- Trial name
- NCT05690711
- Testing
- HRS8179
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
Pharyngitis
A Study of Flurbiprofen 8.75 mg Lozenge in Patients With Pharyngitis
The purposes of this study is to demonstrate the analgesic efficacy of flurbiprofen 8.75 mg lozenge compared to its vehicle lozenge and to demonstrate the safety of the flurbiprofen lozenge throughout the course of treating sore…
- Trial name
- NCT01048866
- Testing
- flurbiprofen, acetaminophen 650mg
- Where
- United States
- Volunteers
- 198 people
- Sponsor
- Reckitt Benckiser LLC
Central Abdominal Bulging
Safety and Efficacy Study of LIPO-202 for the Reduction of Central Abdominal Bulging in Obese Subjects
This is a multi-center, randomized, placebo-controlled, double-blind study evaluating the safety and efficacy of LIPO-202 for the reduction of central abdominal bulging in obese subjects.
- Trial name
- NCT02568319
- Testing
- LIPO-202
- Where
- 6 sites in United States
- Volunteers
- 120 people
- Sponsor
- Neothetics, Inc
Central Abdominal Bulging
Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat
This is a multi-center, randomized, double-blinded, placebo-controlled study evaluating the safety and efficacy of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese subjects.
- Trial name
- AbCONTOUR1 (NCT02397499)
- Testing
- LIPO-202
- Where
- 31 sites in United States
- Volunteers
- 800 people
- Sponsor
- Neothetics, Inc
Acute Hemorrhoids
Study to Find Out How Symptoms Severity Changes During the Standard Course of Treatment With the Cream Relief Pro and Suppositories Relief Pro (Active Ingredients Are Fluocortolone + Lidocaine) in Patients Suffering From Twisted and Bulging Veins in the Rectal Area (Acute Hemorrhoids)
In this study researcher wanted to learn more about the changes of biggest twisted and bulging veins in the rectal area (hemorrhoids) and changes of symptoms during a treatment period with the cream Relief Pro and suppositories…
- Trial name
- NCT03757078
- Testing
- Relief Pro cream, Relief Pro rectal suppositories
- Where
- Russia
- Volunteers
- 1,000 people
- Sponsor
- Bayer
Thyroid Eye Disease, Graves Orbitopathy
A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)
Thyroid eye disease (TED) is a rare autoimmune, inflammatory disorder of the orbit and represents the most common extra-thyroidal manifestation of Graves' disease (GD).
- Trial name
- ORBIT (NCT04737330)
- Testing
- Secukinumab
- Where
- 5 sites in Germany
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals